Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer
1098 A 3D tumor-stroma-immune co-culture platform for bispecific antibody screening in pancreatic ductal adenocarcinoma
- 11Garvan Institute of Medical Research, Sydney, NSW, Australia
- 2Inventia Life Science, Alexandria, NSW, Australia
- 3Australian Centre of NanoMedicine, UNSW Sydney, Sydney, NSW, Australia
Related
- Long-Term Drug Screening Identifies PARP Inhibitors as Irinotecan Combination Partners in BRCA1/2-Wild-Type Pancreatic Ductal Adenocarcinoma.
- Stuck in traffic: a bispecific antibody-mediated immune re-engagement after allogeneic stem cell transplantation
- 1187 Safety and efficacy of cesalatamig, a novel PD-1/VEGF bispecific antibody, as monotherapy in PD-(L)1–resistant/refractory NSCLC: Results from global, multicenter, open-label phase 1/2 studies
- Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
- From Dual Targeting to Clinical Validation: A Translational Framework for Bispecific Antibody–Drug Conjugates
BibTeX
@article{porazinski20261098,
title = {{1098 A 3D tumor-stroma-immune co-culture platform for bispecific antibody screening in pancreatic ductal adenocarcinoma}},
author = {Sean Porazinski and Morgan Hamon and Matthieu Spriet and Susan Harrison Uy and Peilin Tian and Christine Yee},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
month = nov,
doi = {10.1136/jitc-2026-sitc2026.1098},
url = {https://doi.org/10.1136/jitc-2026-sitc2026.1098},
note = {CC BY},
}
RIS
TY - JOUR
TI - 1098 A 3D tumor-stroma-immune co-culture platform for bispecific antibody screening in pancreatic ductal adenocarcinoma
AU - Sean Porazinski
AU - Morgan Hamon
AU - Matthieu Spriet
AU - Susan Harrison Uy
AU - Peilin Tian
AU - Christine Yee
PY - 2026
DA - 2026/11/08
JO - Journal for ImmunoTherapy of Cancer
DO - 10.1136/jitc-2026-sitc2026.1098
UR - https://doi.org/10.1136/jitc-2026-sitc2026.1098
SN - 2051-1426
ER -